CoChat

Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials

Kaul, Sanjay · 2017 · Diabetes Care

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

The U.S. Food and Drug Administration (FDA) issued a diabetes guidance in 2008 mandating that all new antidiabetes drugs rule out excess cardiovascular (CV) risk, defined as an upper bound of the two-sided 95% CI for major adverse CV events (MACE) of less than 1.80 preapproval and 1.30 postapproval. Over 25 large, prospective, randomized, controlled clinical trials involving nearly 195,000 subjects thus far have been completed or are ongoing in accordance with this guidance. The results of seven trials have been presented so far—three with dipeptidyl peptidase 4 inhibitors, one with a sodium–glucose cotransporter 2 (SGLT2) inhibitor, and three with glucagon-like peptide 1 receptor agonists (GLP-1 RA). While all seven trials showed noninferiority in the rate of MACE with the use of these agents compared with placebo, three of them revealed CV benefits. Treatment with empagliflozin (an SGLT2 inhibitor) and treatment with liraglutide (a GLP-1 RA) both significantly reduced the risk of MACE, mortality from CV causes, and mortality from any cause when compared with placebo. Treatment with semaglutide, another GLP-1 RA, showed a significantly lower rate of MACE but not mortality from CV or any cause compared with placebo. In all of the trials, the effects of treatment on outcomes were out of proportion to the small differences in glycemic control levels, suggesting that the effects observed were likely unrelated to differences in the glucose-lowering efficacy. Overall, the results of these trials yield a favorable benefit-risk balance for these therapies in mitigating CV risk in patients with type 2 diabetes. More research is needed to elucidate the underlying mechanisms and confirm whether the CV benefits are a class effect or whether the benefits persist in patients without established CV disease or are evident even in patients without diabetes.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc17-0291

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Committee for Medicinal Products for Human Use, 2012, Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus

Cited by

See all 62

Metadata

Authors
Kaul, S.
Affiliations
Cedars-Sinai Medical Center (US)
Corresponding author
Kaul, Sanjay
Venue
Diabetes Care
Published
2017-06-13
Volume
40
Issue
7
Pages
821-831
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2711994541
Cited by
62
References
29
Citations by year
2026: 2 · 2025: 4 · 2023: 2 · 2022: 5 · 2021: 6 · 2020: 8 · 2019: 11 · 2018: 18 · 2017: 6
FWCI
1.71
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
type 2 diabetes, cardiovascular risk, major adverse cardiovascular events, empagliflozin, liraglutide, semaglutide, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, EMPA-REG OUTCOME, LEADER trial, SUSTAIN 6 trial, benefit-risk balance, cardiovascular mortality
MeSH terms
Liraglutide, Semaglutide, Animals, Benzhydryl Compounds, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glucosides, Humans, Hypoglycemic Agents, Risk Factors, Randomized Controlled Trials as Topic, Treatment Outcome, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.